SAN DIEGO, March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 101,200 shares of its common stock and 50,900 restricted stock units ("RSUs") to sixteen (16) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees

On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts  Plan to present functional data in fourth quarter of 2025 Investor and analyst webcast event today at 8:00 a.m. ET SAN DIEGO, March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive del-zota topline data from the Phase 1/2 EXPLORE44® trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) demons

Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m. CT/8:00 a.m. ET SAN DIEGO, March 12, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therap

SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. "Rare Disease Day represents an important opportunity for al

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission  Commercial preparations well underway in anticipation of three potential successive product launches for DMD, DM1 and FSHD starting in 2026 Phase 1/2 EXPLORE44® top-line del-zota data to be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceut

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 p.m. ETLeerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00 p.m. ETBarclays 27th Annual Global Healthcare Conference on Wednesday,

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,000 shares of its common stock and 53,500 restricted stock units ("RSUs") to twenty-two (22) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the emplo

SAN DIEGO, Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 10,500 shares of its common stock and 5,250 restricted stock units ("RSUs") to one (1) new non-executive employee under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees enteri

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common stock and 40,000 restricted stock units ("RSUs") to Charles Calderaro III, under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"), in connection with Mr. Calderaro's hiring and appointment as Avidity's Chief Technic

Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025   On track to complete enrollment in del-desiran HARBORTM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025    Eric Mosbrooker expands role to Chief Commercial Officer; Charles Calderaro III, Chief Technical Officer, and Kat Lange, Chief Business Officer, join as company prepares for global commercialization and continued pipeline expansion   Avidity to present at 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, I

Citigroup initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $70.00

BMO Capital Markets initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $72.00

Scotiabank initiated coverage of Avidity Biosciences with a rating of Sector Outperform and set a new price target of $70.00

H.C. Wainwright initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $72.00

RBC Capital Mkts initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $67.00

Goldman initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $59.00

Barclays initiated coverage of Avidity Biosciences with a rating of Overweight and set a new price target of $63.00

BofA Securities initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $40.00

Cantor Fitzgerald initiated coverage of Avidity Biosciences with a rating of Overweight and set a new price target of $60.00

Evercore ISI upgraded Avidity Biosciences from In-line to Outperform and set a new price target of $20.00

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

144 - Avidity Biosciences, Inc. (0001599901) (Subject)

S-8 - Avidity Biosciences, Inc. (0001599901) (Filer)

10-K - Avidity Biosciences, Inc. (0001599901) (Filer)

8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

SCHEDULE 13G - Avidity Biosciences, Inc. (0001599901) (Subject)

8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

SAN DIEGO, May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases. 

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

SAN DIEGO, Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "Today, on Rare Disease Day, we are proud to join the global community in raising awareness for people living with rare diseases," said Sarah Boyce, president and chief exe

Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living with DM1 at MDA Clinical & Scientific Conference and via webcast on March 4, 2024  Avidity to report data from clinical programs for people living with FSHD and DMD44 later this year SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2023, and highli

Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H -- Avidity to advance wholly-owned and partnered cardiology programs toward clinical development Avidity appoints Eric B. Mosbrooker as Chief Strategy Officer SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its 2024 corporate priorities and catalysts for the next

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies. "Steve brings a unique combination of extensive experience in the RNA field as well as a deep understanding of rare disease drug deve

LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of experienced global commercial and operations executive, Eric Mosbrooker to its board of directors. Mr. Mosbrooker is an industry leader with expertise in building global commercial organizations, as well as marketing, market access, distribution, and compliance. The company also announced the departure of Roderick Wong, M.

Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates

Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A

SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13D/A - Avidity Biosciences, Inc. (0001599901) (Subject)

SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)